Last reviewed · How we verify
Lotemax
At a glance
| Generic name | Lotemax |
|---|---|
| Also known as | Lotemax (loteprednol etabonate) 0.5%, Loteprednol, loteprednol etabonate ophthalmic gel 0.5% |
| Sponsor | Tufts Medical Center |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Allergic conjunctivitis
- Anterior uveitis
- Corneal abrasion
- Herpes zoster keratitis
- Herpes zoster keratoconjunctivitis
- Iridocyclitis
- Iritis
- Ocular rosacea
- Perforation of cornea
- Post-Op Ocular Inflammation
- Punctate keratitis
- Rosacea
- Uveitis
Common side effects
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain (NA)
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period (PHASE4)
- Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus (EARLY_PHASE1)
- Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection (PHASE4)
- The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED (PHASE4)
- Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax (PHASE4)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |